Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label SLV308 safety extension in Parkinson's disease with motor fluctuations
2006-005183-91Phase 3Completed
- Sponsor
- Solvay
- Start
- Dec 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of pardoprunox in Parkinson's disease (PD), sponsored by Solvay. Primary endpoint: Long-term safety and tolerability of SLV308. Started Dec 2006; status: completed.
02
Drugs
pardoprunox
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2006-005183-91.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005183-91.